Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
July 21 2021 - 08:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE
ISSUER PURSUANT TO RULE 13a-16
OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT
OF 1934
For the month of July 2021
Commission File Number: 001-36582
Auris
Medical Holding Ltd.
(Exact name of registrant as specified in its
charter)
Clarendon House, 2 Church Street
Hamilton HM 11, Bermuda
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes ☐ No ☒
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes ☐ No ☒
Special General Meeting Results
On July 21, 2021, Auris Medical Holding Ltd. (the
“Company”) held its Special General Meeting of Shareholders (the “Meeting”). The final results of
each of the agenda items submitted to a vote of the shareholders are as follows:
Agenda Item 1: Change of Company Name
The shareholders of the Company approved the change
of the Company’s name to Altamira Therapeutics Ltd., effective upon the issuance of a certificate of incorporation on change of
name from the Bermuda Registrar of Companies.
Agenda Item 2: Election of Director
The Company’s shareholders elected Margrit
Schwarz as a member of the Board of Directors, to hold office until the 2022 Annual General Meeting of shareholders or until her successor
is elected or appointed or her office is otherwise vacated.
Other Items
At the Meeting, the Chairman announced that the
Company’s shares are expected to start trading under the new name and the ticker symbol “CYTO,” instead of “EARS,”
on Monday, July 26, 2021 at the earliest.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Auris Medical Holding Ltd.
|
|
|
|
By:
|
/s/ Thomas Meyer
|
|
|
Name:
|
Thomas Meyer
|
|
|
Title:
|
Chairman and Chief Executive Officer
|
Date: July 21, 2021
2
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Mar 2023 to Mar 2024